el-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, Schwartz T
Israel Defense Forces Medical Corps, Jerusalem.
J Infect Dis. 1990 Mar;161(3):446-8. doi: 10.1093/infdis/161.3.446.
Persistence of neutralizing antibodies after revaccination against smallpox was studied. Single serum samples from 140 revaccinated donors were tested for neutralizing antibodies using the plaque reduction assay. The donors, aged 21-49 years at sampling, had been vaccinated in infancy and revaccinated at 8 and 18 years; they formed seven groups of 20 men each, revaccinated about 3, 5, 10, 15, 20, 25, and 30 years before sampling. The differences in mean titer among groups were insignificant (P greater than .01). The titer significantly decreased during the first 3 years after the revaccination but remained stable for at least 30 years thereafter (geometric mean titer, 10.5; 95% confidence interval, 6.8-16.4). The results suggest that there is probably no need for routine revaccinations beyond the primary and two revaccinations; nevertheless, persons at high risk should be revaccinated regardless of their vaccination status.
对再次接种天花疫苗后中和抗体的持久性进行了研究。使用蚀斑减少试验对140名再次接种疫苗的供血者的单次血清样本进行了中和抗体检测。采样时年龄在21至49岁之间的供血者在婴儿期接种过疫苗,并在8岁和18岁时再次接种;他们分成七组,每组20名男性,在采样前约3、5、10、15、20、25和30年再次接种。各组之间平均滴度的差异不显著(P大于0.01)。再次接种后的前3年滴度显著下降,但此后至少30年保持稳定(几何平均滴度为10.5;95%置信区间为6.8至16.4)。结果表明,除了初次接种和两次再次接种外,可能无需进行常规再次接种;不过,高危人群无论其接种状况如何都应再次接种。